Trending NewsTrending NewsNYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis $39.48 +0.17 (+0.44%) Closing price 03:59 PM EasternExtended Trading$39.48 -0.01 (-0.02%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Teva Pharmaceutical Industries Stock (NYSE:TEVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TEVA alerts:Sign Up Key Stats Today's Range$39.05▼$39.8150-Day Range$30.78▼$40.1852-Week Range$18.83▼$40.79Volume4.77 million shsAverage Volume6.81 million shsMarket Capitalization$46.01 billionP/E Ratio65.80Dividend YieldN/APrice Target$44.67Consensus RatingModerate Buy Company Overview Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars. Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia. The company also supplies a broad range of generic medicines in multiple dosage forms. Teva serves patients, healthcare providers and pharmaceutical partners in markets across North America, Europe and other international regions. The company is led by President and Chief Executive Officer Richard Francis, who assumed the role in 2023.AI Generated. May Contain Errors. Read More Teva Pharmaceutical Industries Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreTEVA MarketRank™: Teva Pharmaceutical Industries scored higher than 73% of companies evaluated by MarketBeat, and ranked 160th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialTeva Pharmaceutical Industries has a consensus price target of $44.67, representing about 13.1% upside from its current price of $39.48.Amount of Analyst CoverageTeva Pharmaceutical Industries has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Teva Pharmaceutical Industries' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth55.44% Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 55.44% in the coming year, from $1.93 to $3.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is 65.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is 65.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.42.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 3.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Teva Pharmaceutical Industries' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.72% of the float of Teva Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 27.35, which indicates bearish sentiment.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently increased by 11,467.47%, indicating that investor sentiment is decreasing significantly. Dividend0.8 / 5Dividend StrengthN/A Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.70% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend. News and Social Media2.9 / 5News Sentiment0.59 News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.Search InterestOnly 7 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,644,285.00 in company stock.Percentage Held by Insiders0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Teva Pharmaceutical Industries' insider trading history. Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Stock News HeadlinesTeva's Ecopipam Shows Sustained Tic Reduction In Pediatric Tourette Syndrome3 hours ago | rttnews.comConsensus price target for Teva Pharmaceutical Industries raised 24.24% to ₪41.82October 2 at 9:40 AM | msn.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.October 2 at 1:00 AM | Stansberry Research (Ad)Teva Pharmaceutical Industries Ltd: Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette SyndromeOctober 2 at 9:40 AM | finanznachrichten.deTeva Pharmaceutical Industries Limited - Depositary receipt price target increased by 19.98% to $0.13October 2 at 9:40 AM | msn.comTeva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette SyndromeOctober 2 at 9:40 AM | rttnews.comTeva Pharmaceutical Industries Ltd: Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism ...October 2 at 9:40 AM | finanznachrichten.deInsider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells $285,236.70 in StockSeptember 23, 2026 | insidertrades.comSee More Headlines TEVA Stock Analysis - Frequently Asked Questions How have TEVA shares performed this year? Teva Pharmaceutical Industries' stock was trading at $31.21 at the start of the year. Since then, TEVA stock has increased by 26.5% and is now trading at $39.4820. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced its earnings results on Tuesday, June, 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The business earned $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a trailing twelve-month return on equity of 32.64%. Read the conference call transcript. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T). Company Calendar Last Earnings6/30/2026Today10/02/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TEVA's financial health is in the Green zone, according to TradeSmith. TEVA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:TEVA CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees33,950Year Founded1901Price Target and Rating Average Price Target for Teva Pharmaceutical Industries$44.67 High Price Target$55.00 Low Price Target$40.00 Potential Upside/Downside+13.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$0.60 Trailing P/E Ratio65.80 Forward P/E Ratio20.46 P/E Growth3.77Net Income$1.41 billion Net Margins4.08% Pretax Margin4.09% Return on Equity32.64% Return on Assets6.34% Debt Debt-to-Equity Ratio1.56 Current Ratio0.88 Quick Ratio0.67 Sales & Book Value Annual Sales$17.26 billion Price / Sales2.67 Cash Flow$3.72 per share Price / Cash Flow10.62 Book Value$6.88 per share Price / Book5.74Miscellaneous Outstanding Shares1,165,300,000Free Float1,159,003,000Market Cap$46.01 billion OptionableOptionable Beta0.89 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:TEVA) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TEVA Stock Alerts